Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Advancing progress for patients with cancer through small business innovation research
Norman E. Sharpless
Norman E. Sharpless
Published June 2, 2020
Citation Information: J Clin Invest. 2020;130(7):3339-3341. https://doi.org/10.1172/JCI138643.
View: Text | PDF
Viewpoint Article has an altmetric score of 1

Advancing progress for patients with cancer through small business innovation research

  • Text
  • PDF
Abstract

Authors

Norman E. Sharpless

×

Figure 1

Commercialization resources available at NCI SBIR Development Center.

Options: View larger image (or click on image) Download as PowerPoint
Commercialization resources available at NCI SBIR Development Center.
SB...
SBIR/STTR offers funding opportunities for 3 phases of technology development. Phase I is the initial proof-of-concept phase. Phase II is a fuller research-and-development stage of successful Phase I projects. The Phase IIB Bridge facilitates acceleration of project commercialization, a critical period commonly referred to as the “Valley of Death,” during which many companies fail. The Bridge was specifically instituted to deal with startups’ need for resources to advance their technology to a key inflection point — typically into human clinical trials. As early investment from the NCI has decreased the risk of failure for projects entering Phase IIB, projects have a high success rate for commercialization. Of note, the major distinguishing feature of the STTR program from the SBIR program is that projects must involve a cooperative research-and-development arrangement between small businesses and research institutions. Additionally, the project director/principal investigator in the STTR program is not required to have his/her main employment from the small business for the duration of the grant. For more information on these programs and resources, see https://sbir.cancer.gov/programseducation.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 3 X users
13 readers on Mendeley
See more details